BCR/ABL-mediated increased expression of multiple genes implicated in the pathogenesis of chronic myelogenous leukemia

被引：0
|
作者：
Salesse, S [1 ]
Verfaillie, C [1 ]
机构：
[1] Univ Minnesota, Minneapolis, MN 55455 USA
来源：
EXPERIMENTAL HEMATOLOGY | 2002年 / 30卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
406
引用
收藏
页码：138 / 138
页数：1
相关论文
共 50 条
  • [31] BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia
    Salesse, S
    Verfaillie, CM
    ONCOGENE, 2002, 21 (56) : 8547 - 8559
  • [32] BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia
    Stephanie Salesse
    Catherine M Verfaillie
    Oncogene, 2002, 21 : 8547 - 8559
  • [33] Analysis of gene expression generated by the presence of the BCR-ABL gene in Chronic Myelogenous Leukemia cells
    Lerma, E
    Eckhardt, C
    Kim, W
    McClelland, M
    Deisseroth, A
    EXPERIMENTAL HEMATOLOGY, 2003, 31 (07) : 226 - 227
  • [34] The dual expression of minor and major bcr/abl chimeric mRNA in blast crisis of chronic myelogenous leukemia
    Tanaka, M
    Yamazaki, Y
    Hattori, M
    Tsushita, K
    Utsumi, M
    Yoshida, S
    LEUKEMIA RESEARCH, 1996, 20 (07) : 575 - 580
  • [35] BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells
    Brauer, Katharina M.
    Werth, Daniela
    von Schwarzenberg, Karin
    Bringmann, Anita
    Kanz, Lothar
    Gruenebach, Frank
    Brossart, Peter
    CANCER RESEARCH, 2007, 67 (11) : 5489 - 5497
  • [36] Is there an entity of chemically induced BCR-ABL-positive chronic myelogenous leukemia?
    Lichtman, Marshall A.
    ONCOLOGIST, 2008, 13 (06): : 645 - 654
  • [37] RAS IS ESSENTIAL FOR TRANSFORMATION BY THE BCR-ABL ONCOGENE OF CHRONIC MYELOGENOUS LEUKEMIA
    SAWYERS, CL
    MCLAUGHLIN, J
    HAVLIK, M
    WITTE, O
    BLOOD, 1993, 82 (10) : A331 - A331
  • [38] BCR-ABL - AN ANTI-APOPTOSIS GENE IN CHRONIC MYELOGENOUS LEUKEMIA
    COTTER, TG
    LEUKEMIA & LYMPHOMA, 1995, 18 (3-4) : 231 - 236
  • [39] Status of bcr-abl tyrosine kinase inhibitors in chronic myelogenous leukemia
    O'Dwyer, ME
    Druker, BJ
    CURRENT OPINION IN ONCOLOGY, 2000, 12 (06) : 594 - 597
  • [40] Nilotinib Therapy in Chronic Myelogenous Leukemia: The Strength of High Selectivity on BCR/ABL
    Breccia, Massimo
    Alimena, Giuliana
    CURRENT DRUG TARGETS, 2009, 10 (06) : 530 - 536
12345